Structural and Biochemical Evaluation of Bisubstrate Inhibitors of Protein Arginine N-methyltransferases PRMT1 and CARM1 (PRMT4)

Overview

Journal Biochem J

Specialty Biochemistry

Date 2020 Feb 4

PMID 32011657

Citations 4

Authors

Emma A Gunnell

Alaa Al-Noori

Usama Muhsen

Clare C Davies

James Dowden

Ingrid Dreveny

Affiliations

Soon will be listed here.

Abstract

Attenuating the function of protein arginine methyltransferases (PRMTs) is an objective for the investigation and treatment of several diseases including cardiovascular disease and cancer. Bisubstrate inhibitors that simultaneously target binding sites for arginine substrate and the cofactor (S-adenosylmethionine (SAM)) have potential utility, but structural information on their binding is required for their development. Evaluation of bisubstrate inhibitors featuring an isosteric guanidine replacement with two prominent enzymes PRMT1 and CARM1 (PRMT4) by isothermal titration calorimetry (ITC), activity assays and crystallography are reported. Key findings are that 2-aminopyridine is a viable replacement for guanidine, providing an inhibitor that binds more strongly to CARM1 than PRMT1. Moreover, a residue around the active site that differs between CARM1 (Asn-265) and PRMT1 (Tyr-160) is identified that affects the side chain conformation of the catalytically important neighbouring glutamate in the crystal structures. Mutagenesis data supports its contribution to the difference in binding observed for this inhibitor. Structures of CARM1 in complex with a range of seven inhibitors reveal the binding modes and show that inhibitors with an amino acid terminus adopt a single conformation whereas the electron density for equivalent amine-bearing inhibitors is consistent with preferential binding in two conformations. These findings inform the molecular basis of CARM1 ligand binding and identify differences between CARM1 and PRMT1 that can inform drug discovery efforts.

Citing Articles

PRMT3 and CARM1: Emerging Epigenetic Targets in Cancer.

Huang J, Qiao B, Yuan Y, Xie Y, Xia X, Li F J Cell Mol Med. 2025; 29(4):e70386.

PMID: 39964832 PMC: 11834966. DOI: 10.1111/jcmm.70386.

Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1.

Hendrickson-Rebizant T, Sudhakar S, Rowley M, Frankel A, Davie J, Lakowski T J Med Chem. 2024; 67(18):15931-15946.

PMID: 39250434 PMC: 11440505. DOI: 10.1021/acs.jmedchem.4c00490.

Structure-guided design of a selective inhibitor of the methyltransferase KMT9 with cellular activity.

Wang S, Klein S, Urban S, Staudt M, Barthes N, Willmann D Nat Commun. 2024; 15(1):43.

PMID: 38167811 PMC: 10762027. DOI: 10.1038/s41467-023-44243-6.

A unique binding pocket induced by a noncanonical SAH mimic to develop potent and selective PRMT inhibitors.

Deng Y, Song X, Iyamu I, Dong A, Min J, Huang R Acta Pharm Sin B. 2023; 13(12):4893-4905.

PMID: 38045046 PMC: 10692381. DOI: 10.1016/j.apsb.2023.07.022.

Discovery of a potent and dual-selective bisubstrate inhibitor for protein arginine methyltransferase 4/5.

Al-Hamashi A, Chen D, Deng Y, Dong G, Huang R Acta Pharm Sin B. 2021; 11(9):2709-2718.

PMID: 34589391 PMC: 8463262. DOI: 10.1016/j.apsb.2020.10.013.

References

Greenblatt S, Man N, Hamard P, Asai T, Karl D, Martinez C . CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell. 2018; 33(6):1111-1127.e5. PMC: 6191185. DOI: 10.1016/j.ccell.2018.05.007. View

Guccione E, Richard S . The regulation, functions and clinical relevance of arginine methylation. Nat Rev Mol Cell Biol. 2019; 20(10):642-657. DOI: 10.1038/s41580-019-0155-x. View

Di Lorenzo A, Bedford M . Histone arginine methylation. FEBS Lett. 2010; 585(13):2024-31. PMC: 3409563. DOI: 10.1016/j.febslet.2010.11.010. View

Moriarty N, Grosse-Kunstleve R, Adams P . electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr D Biol Crystallogr. 2009; 65(Pt 10):1074-80. PMC: 2748967. DOI: 10.1107/S0907444909029436. View

Sack J, Thieffine S, Bandiera T, Fasolini M, Duke G, Jayaraman L . Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem J. 2011; 436(2):331-9. DOI: 10.1042/BJ20102161. View

Wang H, Huang Z, Xia L, Feng Q, Erdjument-Bromage H, Strahl B . Methylation of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hormone receptor. Science. 2001; 293(5531):853-7. DOI: 10.1126/science.1060781. View

Yang H, Ouyang Y, Ma H, Cong H, Zhuang C, Lok W . Design and synthesis of novel PRMT1 inhibitors and investigation of their binding preferences using molecular modelling. Bioorg Med Chem Lett. 2017; 27(20):4635-4642. DOI: 10.1016/j.bmcl.2017.09.016. View

Drew A, Moradei O, Jacques S, Rioux N, Boriack-Sjodin A, Allain C . Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Sci Rep. 2017; 7(1):17993. PMC: 5740082. DOI: 10.1038/s41598-017-18446-z. View

Morales Y, Caceres T, May K, Hevel J . Biochemistry and regulation of the protein arginine methyltransferases (PRMTs). Arch Biochem Biophys. 2015; 590:138-152. DOI: 10.1016/j.abb.2015.11.030. View

10.

Lakowski T, t Hart P, Ahern C, Martin N, Frankel A . Nη-substituted arginyl peptide inhibitors of protein arginine N-methyltransferases. ACS Chem Biol. 2010; 5(11):1053-63. DOI: 10.1021/cb100161u. View

11.

Hong H, Kao C, Jeng M, Eble J, Koch M, Gardner T . Aberrant expression of CARM1, a transcriptional coactivator of androgen receptor, in the development of prostate carcinoma and androgen-independent status. Cancer. 2004; 101(1):83-9. DOI: 10.1002/cncr.20327. View

12.

Dillon M, Bachovchin D, Brown S, Finn M, Rosen H, Cravatt B . Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization. ACS Chem Biol. 2012; 7(7):1198-204. PMC: 3401332. DOI: 10.1021/cb300024c. View

13.

Chen D, Ma H, Hong H, Koh S, Huang S, Schurter B . Regulation of transcription by a protein methyltransferase. Science. 1999; 284(5423):2174-7. DOI: 10.1126/science.284.5423.2174. View

14.

van Haren M, Marechal N, Troffer-Charlier N, Cianciulli A, Sbardella G, Cavarelli J . Transition state mimics are valuable mechanistic probes for structural studies with the arginine methyltransferase CARM1. Proc Natl Acad Sci U S A. 2017; 114(14):3625-3630. PMC: 5389282. DOI: 10.1073/pnas.1618401114. View

15.

Cheng D, Cote J, Shaaban S, Bedford M . The arginine methyltransferase CARM1 regulates the coupling of transcription and mRNA processing. Mol Cell. 2007; 25(1):71-83. DOI: 10.1016/j.molcel.2006.11.019. View

16.

Zhang X, Cheng X . Structure of the predominant protein arginine methyltransferase PRMT1 and analysis of its binding to substrate peptides. Structure. 2003; 11(5):509-20. PMC: 4030380. DOI: 10.1016/s0969-2126(03)00071-6. View

17.

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View

18.

van Haren M, Quarles van Ufford L, Moret E, Martin N . Synthesis and evaluation of protein arginine N-methyltransferase inhibitors designed to simultaneously occupy both substrate binding sites. Org Biomol Chem. 2014; 13(2):549-60. DOI: 10.1039/c4ob01734j. View

19.

Yang J, Copeland R, Lai Z . Defining balanced conditions for inhibitor screening assays that target bisubstrate enzymes. J Biomol Screen. 2009; 14(2):111-20. DOI: 10.1177/1087057108328763. View

20.

Blanc R, Richard S . Arginine Methylation: The Coming of Age. Mol Cell. 2017; 65(1):8-24. DOI: 10.1016/j.molcel.2016.11.003. View